Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760584 | 0.81 | NOTUM (0.50) | NOTUMTNFNOD2NOD1KMT2A | |
| SCHEMBL1760583 | 0.81 | NOTUM (0.50) | NOTUMLMNAKMT2A | |
| SCHEMBL2205547 | 0.81 | LMNA (0.68) | NOTUMLMNATNFNOD2NOD1 | |
| SCHEMBL12428954 | 0.81 | LMNA (0.68) | NOTUMLMNATNFNOD2NOD1 | |
| SCHEMBL2209599 | 0.81 | LMNA (0.68) | NOTUMLMNATNFNOD2NOD1 | |
| SCHEMBL7316200 | 0.78 | NOTUM (0.51) | NOTUMLMNATNFNOD2NOD1 | |
| SCHEMBL1760604 | 0.77 | NOTUM (0.62) | NOTUMLMNAHSD17B3 | |
| SCHEMBL1760607 | 0.77 | NOTUM (0.62) | NOTUMLMNAHSD17B3 | |
| SCHEMBL1760527 | 0.77 | LMNA (0.50) | NOTUMLMNATNFNOD2NOD1 | |
| SCHEMBL7316205 | 0.76 | LMNA (0.49) | NOTUMLMNATNFNOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247432-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-21 | — | — | US | disclosed |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY JOSEPH | 2011-09-15 | — | — | US | disclosed |
| US-7947713-B2 | (3-(4-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-isoquinoline; inactivation of endogenous neuropeptides such as cholecystokinis; eating disorders, obesity, psychotic syndromes and associated psychiatric disorders; chemical intermediates coupling | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY J | 2008-05-08 | — | — | US | disclosed |
| EP-1392291-B1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | BRESLIN HENRY J | 2006-12-07 | — | — | US | disclosed |
| US-7125891-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-24 | — | — | US | disclosed |
| EP-1392291-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| WO-2002036116-A9 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002036116-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | NOTUM 1728/4885LMNA 2218/4885TNF 4672/4885 |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | NOTUM 1373/4885LMNA 2634/4885TNF 4619/4885 |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | NOTUM 1373/4885LMNA 2634/4885TNF 4619/4885 |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | NOTUM 1373/4885LMNA 2634/4885TNF 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.